Appropriate Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Atherosclerotic Cardiovascular Disease: Comparison of Recommendations from Different Guidelines or Consensus Around the World
Acta Cardiologica Sinica, 2020-09, Vol.36 (5), p.403-408ISSN: 1011-6842 ;DOI: 10.6515/ACS.202009_36(5).20200330B ;PMID: 32952349
Full text available